Urethra-sparing stereotactic body radiotherapy for prostate cancer: how much can the rectal wall dose be reduced with or without an endorectal balloon?

前列腺癌尿道保留立体定向放射治疗:使用或不使用直肠内球囊,直肠壁剂量可以减少多少?

阅读:1

Abstract

BACKGROUND: This is a dosimetric comparative study intended to establish appropriate low-to-intermediate dose-constraints for the rectal wall (R(wall)) in the context of a randomized phase-II trial on urethra-sparing stereotactic body radiotherapy (SBRT) for prostate cancer. The effect of plan optimization on low-to-intermediate R(wall) dose and the potential benefit of an endorectal balloon (ERB) are investigated. METHODS: Ten prostate cancer patients, simulated with and without an ERB, were planned to receive 36.25Gy (7.25Gyx5) to the planning treatment volume (PTV) and 32.5Gy to the urethral planning risk volume (uPRV). Reference plans with and without the ERB, optimized with respect to PTV and uPRV coverage objectives and the organs at risk dose constraints, were further optimized using a standardized stepwise approach to push down dose constraints to the R(wall) in the low to intermediate range in five sequential steps to obtain paired plans with and without ERB (Vm(1) to Vm(5)). Homogeneity index for the PTV and the uPRV, and the Dice similarity coefficient (DSC) for the PTV were analyzed. Dosimetric parameters for R(wall) including the median dose and the dose received by 10 to 60% of the R(wall), bladder wall (B(wall)) and femoral heads (F(Heads)) were compared. The monitor units (MU) per plan were recorded. RESULTS: Vm(4) reduced by half D(30%), D(40%), D(50%,) and D(med) for R(wall) and decreased by a third D(60%) while HI(PTV), HI(uPRV) and DSC remained stable with and without ERB compared to Vm(ref). HI(PTV) worsened at Vm(5) both with and without ERB. No statistical differences were observed between paired plans on R(wall), B(wall) except a higher D(2%) for F(heads) with and without an ERB. CONCLUSIONS: Further optimization to the R(wall) in the context of urethra sparing prostate SBRT is feasible without compromising the dose homogeneity to the target. Independent of the use or not of an ERB, low-to-intermediate doses to the R(wall) can be significantly reduced using a four-step sequential optimization approach.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。